CME Travel Academy clinical update graphic: oral GLP-1 treatment for obesity, orforglipron, SELECT trial, 20% MACE risk reduction, 11.2% weight loss, 12 CME hours

Oral GLP-1 Treatment for Obesity: Orforglipron, the SELECT Trial, and the New 2026 Primary Care Playbook

By Dr. Vimal George, MD | Reviewed by CME Travel Academy Faculty8 min read  ·  Reviewed July 2026 Accredited CME: ✓ AMA PRA Category 1 Credit™ ✓ AAFP Prescribed ✓ AOA Category 2 ✓ 12 Credits per Conference In this article: Obesity Is Now a Cardiovascular Diagnosis Orforglipron Changes the Access Equation Injectable Incretins Still

Oral GLP-1 Treatment for Obesity: Orforglipron, the SELECT Trial, and the New 2026 Primary Care Playbook Read More »

Walt Disney World CME Conference 2026: Earn 12 CME Credits at the Most Magical Place on Earth

What if your next CME requirement came with a side of roller coasters, a waterfront dinner, and a family vacation? That’s not a hypothetical — it’s July 17–18, 2026 at CME Travel Academy’s Walt Disney World CME Conference, held at the Drury Plaza Hotel in the Disney Springs® Area, Orlando, Florida. This is accredited, evidence-based

Walt Disney World CME Conference 2026: Earn 12 CME Credits at the Most Magical Place on Earth Read More »